NHD Global
Continue from catalog navigation into editorial analysis, evidence records and quality-documentation guidance.
Showing 19–24 of 27 reviewed articles · Page 4 of 5
The best-known CJC-1295 human studies tested an albumin-binding DAC construct. A product labeled “CJC-1295 without DAC” lacks that defining feature, so quoting…
Read source review →For CJC-1295 with DAC, the albumin-reactive group is not a branding detail. It changes persistence, analytical behavior and the relevance of the…
Read source review →The classic CJC-1295 human paper evaluated a long-acting albumin-binding analog in healthy adults. Its sustained hormone profile is evidence for the DAC…
Read source review →Ipamorelin evidence is route- and protocol-specific. FDA’s current review notes immunogenicity and impurity concerns, unnatural amino-acid characterization complexity and insufficient safety information…
Read source review →Ipamorelin was tested in a multicenter, double-blind, placebo-controlled bowel-resection study. The median result numerically favored ipamorelin, but the difference was not statistically…
Read source review →MK-677, MK-0677 and ibutamoren are names found across the same development history. The existence of human trials does not mean the compound…
Read source review →If a target is not listed, submit the sequence, scale and specification for a custom-project feasibility review.
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
